Sinocare (SZSE:300298) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Sinocare Change In Receivables?

Sinocare's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Sinocare's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Sinocare's change in receivables for the fiscal year that ended in Dec. 2023 was ¥111 Mil. It means Sinocare's Accounts Receivable declined by ¥111 Mil from Dec. 2022 to Dec. 2023 .

Sinocare's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥547 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sinocare's Days Sales Outstanding for the three months ended in Mar. 2024 was 49.27.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sinocare's liquidation value for the three months ended in Mar. 2024 was ¥-913 Mil.

Sinocare Change In Receivables Historical Data

The historical data trend for Sinocare's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinocare Change In Receivables Chart

Sinocare Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-49.59

-181.29

11.98

-184.49

110.92

Sinocare Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Sinocare Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

Sinocare (SZSE:300298) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sinocare's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	547.319	/	1013.58	*	91
=	49.27

2. In Ben Graham's calculation of liquidation value, Sinocare's accounts receivable are only considered to be worth 75% of book value:

Sinocare's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	672.599	-	2307.888	+	0.75 * 547.319	+	0.5 * 622.683
=	-913

Sinocare Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sinocare's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinocare (SZSE:300298) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sinocare Inc (SZSE:300298) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.265 Guyuan Road, Hi-tech Zone, Hunan Province, Changsha, CHN, 410205

Website

https://en.sinocare.com/

Sinocare Inc operates in the healthcare industry. It is engaged in the development, manufacturing, and marketing of diagnosis testing products for people with chronic diseases and healthcare professionals. Its product range covers household blood glucose meter, medical blood glucose meter, urinary microalbumin test strip and blood lipid uric acid products. In addition, the company also provides diabetes management information systems.

Executives

Li Shao Bo	Directors, executives
Che Hong Jing	Director
Wang Shi Min	Executives
Huang An Guo	Directors, executives
	Directors, executives
Pan Shu Guang	Securities Affairs Representative
Zhou Qing Hua	Supervisors
Ning Gui Chun	Supervisors
Wang Rui	Securities Affairs Representative
Chen Ji Dong	Supervisors
Che Hong Li	Directors, executives
Zhang Fan	Director

Sinocare (SZSE:300298) Headlines

No Headlines